XKRX003060
Market cap94mUSD
Jan 09, Last price
700.00KRW
1D
1.45%
1Q
-22.99%
Jan 2017
-96.49%
Name
Aprogen Biologics Inc
Chart & Performance
Profile
Aprogen pharmaceuticals,Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. The company was formerly known as Schnell Biopharmaceuticals, Inc. and changed its name to Aprogen pharmaceuticals,Inc. in April 2017. Aprogen pharmaceuticals,Inc. was founded in 1960 and is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 87,363,628 34.01% | 65,190,359 15.42% | |||||||
Cost of revenue | 132,962,765 | 57,926,980 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (45,599,137) | 7,263,379 | |||||||
NOPBT Margin | 11.14% | ||||||||
Operating Taxes | 1,947,066 | 1,260,151 | |||||||
Tax Rate | 17.35% | ||||||||
NOPAT | (47,546,203) | 6,003,228 | |||||||
Net income | (118,269,721) -2,218.15% | 5,583,620 -31.09% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 35,574,520 | 244 | |||||||
BB yield | -19.39% | 0.00% | |||||||
Debt | |||||||||
Debt current | 130,720,460 | 134,608,901 | |||||||
Long-term debt | 69,913,837 | 603,620 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 9,558,467 | 9,386,470 | |||||||
Net debt | 52,934,337 | 53,810,668 | |||||||
Cash flow | |||||||||
Cash from operating activities | (33,650,775) | 25,728,188 | |||||||
CAPEX | (28,087,917) | (1,545,199) | |||||||
Cash from investing activities | (95,205,708) | (53,000,826) | |||||||
Cash from financing activities | 115,289,354 | 15,782,353 | |||||||
FCF | 25,056,526 | (192,499,302) | |||||||
Balance | |||||||||
Cash | 10,053,360 | 99,073,617 | |||||||
Long term investments | 137,646,600 | (17,671,765) | |||||||
Excess cash | 143,331,779 | 78,142,334 | |||||||
Stockholders' equity | (180,413,847) | 366,504,224 | |||||||
Invested Capital | 739,661,086 | 568,351,578 | |||||||
ROIC | 1.13% | ||||||||
ROCE | 1.12% | ||||||||
EV | |||||||||
Common stock shares outstanding | 83,225 | 53,652 | |||||||
Price | 2,203.96 -42.35% | 3,822.73 -44.42% | |||||||
Market cap | 183,424,057 -10.57% | 205,096,227 -44.06% | |||||||
EV | 236,358,395 | 339,561,644 | |||||||
EBITDA | (24,201,534) | 9,667,364 | |||||||
EV/EBITDA | 35.12 | ||||||||
Interest | 3,668,234 | 274,408 | |||||||
Interest/NOPBT | 3.78% |